SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:
BofA Securities Health Care Conference 2024
Date: Tuesday, May 14, 2024, at 4:35 p.m. PT
Location: Encore Hotel in Las Vegas, NV
Format: Presentation
H.C. Wainwright 2nd Annual BioConnect Investor Conference
Date: Monday, May 20, 2024, at 4:00 p.m. ET
Location: NASDAQ Headquarters in New York, NY
Format: Fireside Chat
UBS Spring Biotech Symposium
Date: Tuesday, May 21, 2024
Location: New York, NY
Format: One-on-one Meetings
TD Cowen 5th Annual Oncology Innovation Summit
Date: Tuesday, May 28, 2024, at 10:00 a.m. ET
Location: Virtual
Format: Fireside Chat
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.42 |
| Daily Change: | 0.16 3.76 |
| Daily Volume: | 609,315 |
| Market Cap: | US$328.140M |
March 18, 2025 December 10, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
